VISTN Vistin Pharma ASA

Vistin Pharma enters into a long-term renewable energy supply agreement with Statkraft

Vistin Pharma enters into a long-term renewable energy supply agreement with Statkraft

Oslo, Norway, 9 December 2022

Vistin Pharma ASA (Vistin Pharma, OSE: VISTIN) announces that it has entered into a long-term industrial energy agreement with Statkraft, the leading Norwegian energy supplier. The agreement will secure a significant part of Vistin’s electricity demand on competitive terms until 2032. The agreement includes Guarantees of Origin as certification of the renewable energy supply, and starts 1.1.2023.

2022 has been very challenging for Vistin and the Norwegian industry, when it comes to electricity costs, with extreme volatility and record high electricity prices in the NO2 area where Vistin’s fully automated production plant is located.

- This agreement will give Vistin Pharma stable electricity supply at predictable and competitive prices. The agreement helps to secure our competitiveness in the global Metformin market. We are happy that Statkraft by this agreement contributes to the future development of Vistin and thereby allows the company to continue focusing on its growth strategy, says Kjell-Erik Nordby, CEO in Vistin Pharma.

- We are very pleased to conclude another renewable energy contract with the Norwegian industry which confirms that Statkraft offers relevant solutions at competitive terms, says Frode Berntsen, Head of Industry Nordics & Baltics at Statkraft.  

About Vistin Pharma |

Vistin Pharma is a Norwegian pharmaceutical company producing Metformin Hydrochloride (API). The Metformin is also available as Direct Compressible lubricated granules. As a solely dedicated European Metformin producer, Vistin Pharma is a well-positioned supplier to leading pharmaceutical companies. Vistin Pharma is headquartered in Oslo, Norway, and has highly qualified employees and a dedicated manufacturing facility in Kragerø.

About Statkraft |

Statkraft is a leading company in hydropower internationally and Europe's largest generator of renewable energy. The Group produces hydropower, wind power, solar power, gas-fired power and supplies district heating. Statkraft is a global company in energy market operations Statkraft has 4,800 employees in 20 countries.

*****

For further information, please contact:

Alexander Karlsen

CFO

 36 21

 



EN
09/12/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Vistin Pharma ASA

 PRESS RELEASE

Vistin Pharma ASA: Second quarter and YTD 2025 financial results

Vistin Pharma ASA: Second quarter and YTD 2025 financial results Oslo, Norway, 15th of August 2025 Vistin Pharma ASA (VISTN) today announces the financial results for the second quarter of 2025. Revenue in the second quarter ended at MNOK 118 compared to MNOK 106 in Q2 2024. The increase in revenue was driven by 17% higher sales volume. Revenue for first half of 2025 ended at MNOK 233 compared to MNOK 210 YTD last year, an increase of 11%. Second quarter EBITDA ended at MNOK 30 compared to MNOK 27 in Q2 2024, representing 11% increase. EBITDA was positively affected by increased sales...

 PRESS RELEASE

Vistin Pharma ASA: Invitation to Q2 2025 conference call

Vistin Pharma ASA: Invitation to Q2 2025 conference call Oslo, Norway, 08 August 2025 Vistin Pharma ASA will release its second quarter and YTD 2025 results on Friday 15th of August 2025. Vistin Pharma will host a conference call for all shareholders and interested parties at the same day at 08:30 CET. There will be a Q&A session following the management discussion. The conference call will be held in English. The second quarter conference call will be available via web and audio through the following access points: Webcast: Telephone conference (online registration): ***** For fur...

 PRESS RELEASE

Ex dividend NOK 1.25 today

Ex dividend NOK 1.25 today The shares in Vistin Pharma ASA (VISTN) will be traded ex dividend NOK 1.25 as from today, 04.06.2025.

 PRESS RELEASE

Vistin Pharma ASA: Minutes from the annual general meeting 2025

Vistin Pharma ASA: Minutes from the annual general meeting 2025 Oslo, Norway, 22 May 2025 Vistin Pharma ASA (OSE: VISTN), please find attached the minutes from the annual general meeting held today, on the 22 May 2025. For further information, please contact: Alexander KarlsenCFO+47 97 05 36 21 This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachment

 PRESS RELEASE

Disclosure of voting rights at AGM in Vistin Pharma ASA

Disclosure of voting rights at AGM in Vistin Pharma ASA Oslo, Norway, 22 May 2025 In relation to the Annual General Meeting in Vistin Pharma ASA (OSE: VISTN), on the 22th of May, the Company's Chair of the Board, Øyvin Brøymer, has received open proxies to represent a total of 5 156 012 shares in the Company at the AGM, corresponding to 11.63% of the total number of votes and shares in the Company. Together with the 14 509 280 shares held by Øyvin Brøymer through Intertrade Shipping AS, he will represent a total of 19 665 292 votes at the AGM, corresponding to a total of 44,35% of the tota...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch